London, Jan 11, 2026, 16:43 GMT — Market closed.
- AstraZeneca will be removed from the Nasdaq-100 on Jan. 20, with Walmart stepping in as its replacement.
- AstraZeneca shares climbed on Friday in both London and New York markets.
- With the JPMorgan Healthcare Conference kicking off Monday, investors are gearing up for management remarks ahead of the Feb. 10 earnings release.
AstraZeneca shares head into Monday’s session under pressure after Nasdaq announced Walmart will take the drugmaker’s spot in the Nasdaq-100 starting Jan. 20.
This is significant today since index trackers often translate a calendar shift into actual trades. Funds following the Nasdaq-100 usually tweak their holdings near the effective date, causing spikes in volume and short-term price fluctuations.
AstraZeneca’s shares in London finished Friday at 14,216 pence, gaining 0.28%. Over in the U.S., its ADRs closed at $94.65, up 0.68%, per Yahoo Finance.
Nasdaq’s notice confirmed the change will kick in ahead of trading on Tuesday, Jan. 20, the first session after the third Friday. It also reminded investors that U.S. markets close Monday, Jan. 19, for Martin Luther King Jr. Day, shortening the lead-up period.
The mechanics here are simple, though how the market responds isn’t. The Nasdaq-100 includes 100 of the biggest non-financial firms on Nasdaq. Investors track it via ETFs and various index products.
Traders are shifting focus from the index event to comments from major drugmakers in San Francisco. Healthcare dealmakers attending the annual JPMorgan Healthcare Conference anticipate a busier M&A scene in 2026, boosted by relaxed antitrust scrutiny under President Donald Trump, Reuters reported. JPMorgan banker Jeremy Meilman noted that deals previously seen as high regulatory risks are now clearing more easily. PwC’s Kevin Desai added, “We are seeing the need for change-fueling deals.” Reuters
AstraZeneca plans to join the JPMorgan Healthcare Conference from Jan. 12 to Jan. 14. The company has also set Feb. 10 for its full-year and fourth-quarter earnings release, per its investor calendar.
Conference buzz is heating up as big pharma faces a new patent cliff and fewer proven pipeline assets to acquire. The Financial Times reports that nearly 12% of global pharma revenue—roughly $180 billion annually—is at risk from patent expirations in 2027 and 2028, driving companies toward deal-making.
But the index effect often fades fast. Much of the reshuffling is anticipated, with trades dispersed via derivatives or carried out quietly. When risk appetite shifts, forced selling can barely register.
AstraZeneca faces its next challenge quickly: watch for any management hints from the JPMorgan meetings kicking off Monday, followed by the Nasdaq-100 reset on Jan. 20. The next major earnings event arrives Feb. 10.
